Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection.

BRCA1 BRCA2 biliary tract cancers hereditary BRCA cancer somatic mutations

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 04 03 2020
accepted: 22 06 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 10 9 2020
Statut: epublish

Résumé

BRCA-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk of developing other malignancies including cholangiocarcinoma (CCA). Somatic BRCA mutations have been reported in CCA, but they have yet to be utilized in a proband case to identify HBOC in families. Two healthy daughters of a deceased female patient who had had metachronous breast cancer and CCA received genetic counseling to assess their cancer risk. Somatic

Identifiants

pubmed: 32903564
doi: 10.3389/fonc.2020.01292
pmc: PMC7438755
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1292

Informations de copyright

Copyright © 2020 Paradiso, Patruno, Digennaro, Tommasi, Pilato, Argentiero, Brunetti and Silvestris.

Références

Hered Cancer Clin Pract. 2017 May 25;15:7
pubmed: 28559958
Clin Transl Oncol. 2020 Feb;22(2):193-200
pubmed: 31889241
Oncologist. 2017 Jul;22(7):804-810
pubmed: 28487467
Cancer Manag Res. 2019 Mar 22;11:2321-2337
pubmed: 30962720
Oncol Rep. 2014 Jan;31(1):365-9
pubmed: 24145998
Gynecol Oncol. 2019 Nov;155(2):275-279
pubmed: 31481248
Dig Liver Dis. 2016 Mar;48(3):231-41
pubmed: 26769568
J Med Genet. 2005 Sep;42(9):711-9
pubmed: 16141007
Genes Chromosomes Cancer. 2016 Oct;55(10):803-13
pubmed: 27225819
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846

Auteurs

Angelo Virgilio Paradiso (AV)

Experimental Oncology-Center for the Study of Hereditary Cancers, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Scientific Direction, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Margherita Patruno (M)

Experimental Oncology-Center for the Study of Hereditary Cancers, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Maria Digennaro (M)

Experimental Oncology-Center for the Study of Hereditary Cancers, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Stefania Tommasi (S)

Molecular and Pharmacogenetics Diagnostic Laboratory, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Brunella Pilato (B)

Molecular and Pharmacogenetics Diagnostic Laboratory, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Antonella Argentiero (A)

Medical Oncology Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Oronzo Brunetti (O)

Medical Oncology Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Nicola Silvestris (N)

Medical Oncology Unit, IRCCS-Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy.

Classifications MeSH